Business method patents are a relatively new species of patent and there have been several reviews investigating the appropriateness of patenting business methods.
Also one of the SMD LEDs leading manufacturers in the world with 800 employees worldwide. The patents include both composition claims covering isolated DNA molecules and method claims covering the processes of detecting and screening for BRCA mutations. As I wrote earlier, I believe that the Federal Circuit will reverse. 2010) In a landmark 2010 declaratory judgment decision, a Southern District of New York court invalidated claims from seven Myriad patents associated with the BRCA1/2 breast and ovarian cancer genes. A typical invalidated claim includes Claim 1 of Patent No. An isolated DNA coding for a BRCA1 polypeptide, said polypeptide having the amino acid sequence set forth in SEQ ID NO:2.” (The amino acid sequence No. Myriad has now filed its Federal Circuit appeal brief on the merits and argues two main points: (1) that the declaratory judgment plaintiffs had no standing to sue because there was no actual case or controversy between them and Myriad and (2) that Myriad's patents cover inventions that fit well within the broad scope of Section 101 subject matter eligibility.Notice that 35 USC 112 only states that a claim is necessary, but does not provide any information on the structure or format of the claim or claims.It is, therefore, necessary to turn to Title 37 of the CFR to expand upon what is actually required.Although the weaker of its two primary arguments, Myriad led with its case for no standing.